Control ADCs for R&D
Once an antibody is en route as a candidate for antibody-drug conjugate (ADC) development, it is crucial to select suitable payload-linker complexes for ADC formulation and in the meantime, to develop assays that demonstrate the toxicity of the newly formed ADC. In both cases, a “control ADC” with known toxicity against the same target is required to serve as positive control for the assessment of the potency of the new ADC. Via the custom ADC preparation services, Creative Biolabs offers a variety of control ADCs prepared by the conjugation of well-established antibodies and payload-linker complexes. With a large selection of antibodies against numerous cancer targets and scientists with extensive experience in ADC preparation using payload-linker complexes bearing MMAE, DM1, PBD dimer, Duocarmycin, Calicheamicin…, the “control” ADCs from Creative Biolabs are excellent for concept validation and assay development to help with the progression of any R&D projects.
Table 1. List of selected antibodies for control ADC preparation
Antibody
Subclass
Target
Tacatuzumab
IgG1
AFP
Taplitumomab
IgG1
CD19
Denintuzumab
IgG1
CD19
Inotuzumab
IgG4
CD22
Pinatuzumab
IgG1
CD22
Gemtuzumab
IgG4
CD33
Vorsetuzumab
IgG1
CD70
Polatuzumab
IgG1
CD79B
Tucotuzumab
IgG1
EpCAM
Trastuzumab
IgG1
HER2
Capromab
IgG1
FOLH1
Cantuzumab
IgG1
MUC1
Epitumomab
IgG1
MUC1
Lorvotuzumab
IgG1
NCAM1
Indatuximab
IgG4
SDC1
Brentuximab
IgG1
TNFRSF8
Satumomab
IgG1
TAG72
Coltuximab
IgG1
CD19
Gemtuzumab
IgG2
CD33
Lifastuzumab
IgG1
SLC34A2
Sofituzumab
IgG1
MUC16
Bivatuzumab
IgG1
CD44
Denintuzumab
IgG1
CD19
Enfortumab
IgG1
PVRL4
Anetumab
IgG1
MSLN